866-997-4948(US-Canada Toll Free)

Diabetic Retinopathy - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Sep 2013

Category :

Metabolic Disorders

No. of Pages : 150 Pages


Global Markets Directs, \'Diabetic Retinopathy Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Retinopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy. Diabetic Retinopathy Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Diabetic Retinopathy.
  • A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Diabetic Retinopathy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Diabetic Retinopathy Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Diabetic Retinopathy 12
Diabetic Retinopathy Therapeutics under Development by Companies 14
Diabetic Retinopathy Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Diabetic Retinopathy Therapeutics - Products under Development by Companies 22
Diabetic Retinopathy Therapeutics - Products under Investigation by Universities/Institutes 24
Companies Involved in Diabetic Retinopathy Therapeutics Development 25
Oxford BioMedica plc 25
Novagali Pharma SA 26
Antisense Therapeutics Limited 27
Lpath, Inc. 28
BioDiem Ltd 29
RegeneRx Biopharmaceuticals, Inc. 30
ThromboGenics NV 31
R-Tech Ueno, Ltd. 32
Paloma Pharmaceuticals, Inc. 33
Acucela Inc. 34
OcuCure Therapeutics, Inc. 35
Gene Signal International SA. 36
Promedior, Inc. 37
Inotek Pharmaceuticals Corporation 38
Angstrom Pharmaceuticals, Inc. 39
FirstString Research, Inc. 40
Sirnaomics, Inc. 41
Resolvyx Pharmaceuticals, Inc 42
Stelic Institute & Co. 43
Centocor Ortho Biotech, Inc. 44
EyeCyte, Inc. 45
Vascular Pharmaceuticals, Inc. 46
PanOptica, Inc. 47
Targa Therapeutics Corp. 48
EyeGene, Inc. 49
America Stem Cell, Inc. 50
Ampio Pharmaceuticals, Inc. 51
Diabetic Retinopathy - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
ATL-1103 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
iSONEP - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DG-3173 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VCM For Diabetic Retinopathy - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ocriplasmin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
RGN-259 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
PARP Inhibitors - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
INO-6001 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DT-23552 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
STNM-1510 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
RX-20001 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
OC-10X - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Granzyme B/VEGF - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
A-6 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
aganirsen - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
P-529 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
danazol - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
MTP-131 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
AKB-9778 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
BDM-E - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
RTU-007 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
GLY-230 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
A-717 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
MS-553 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
STP-601 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
VEGF/rGel - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
PAN-90806 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
EG-Mirotin - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
FP-002 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
IB-09A0133 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
INO-6002 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
VPI-2690-B - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Stem Cell Therapy For Diabetic Complications - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
VPI-2690-B - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Neuregulins - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Drug For Diabetic Neuropathy And Retinopathy - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
ASC-101 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
V-1932 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
EC-301 Program - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
EC-200 Program - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
C16Y Peptide - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Diabetic Retinopathy Therapeutics - Drug Profile Updates 115
Diabetic Retinopathy Therapeutics - Discontinued Products 137
Diabetic Retinopathy Therapeutics - Dormant Products 138
Diabetic Retinopathy - Product Development Milestones 139
Featured News & Press Releases 139
Jun 03, 2013: Oxford BioMedic Voluntarily Pauses Recruitment Into Phase I Study Of RetinoStat 139
May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 139
May 01, 2012: Promedior To Present Data From Preclinical Studies Of Pentraxin-2 At ARVO Annual Meeting 140
May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting 141
Apr 27, 2012: Ampio Receives US And Canadian Notice Of Allowance Of Patents For Optina 141
Mar 19, 2012: Ampio Announces Positive Preliminary Update On Optina Clinical Trial To Treat Diabetic Macular Edema 142
Feb 09, 2012: Antisense Therapeutics Provides Development Update On ATL1103 143
Dec 07, 2011: Antisense Therapeutics\'s ATL1103 Successfully Progresses Towards Phase II Clinical Trial 145
Nov 21, 2011: Akebia Initiates Phase I Study Of HPTP Inhibitor For Diabetic Macular Edema And Diabetic Retinopathy 147
Nov 07, 2011: ANP Receives Japanese Patent For ATL1103 148

Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 150
Disclaimer 150

List of Table


Number of Products Under Development for Diabetic Retinopathy, H2 2013 12
Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2013 13
Number of Products under Development by Companies, H2 2013 15
Number of Products under Development by Companies, H2 2013 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2013 17
Comparative Analysis by Late Stage Development, H2 2013 18
Comparative Analysis by Mid Clinical Stage Development, H2 2013 19
Comparative Analysis by Early Clinical Stage Development, H2 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 21
Products under Development by Companies, H2 2013 22
Products under Development by Companies, H2 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H2 2013 24
Oxford BioMedica plc, H2 2013 25
Novagali Pharma SA, H2 2013 26
Antisense Therapeutics Limited, H2 2013 27
Lpath, Inc., H2 2013 28
BioDiem Ltd, H2 2013 29
RegeneRx Biopharmaceuticals, Inc., H2 2013 30
ThromboGenics NV, H2 2013 31
R-Tech Ueno, Ltd., H2 2013 32
Paloma Pharmaceuticals, Inc., H2 2013 33
Acucela Inc., H2 2013 34
OcuCure Therapeutics, Inc., H2 2013 35
Gene Signal International SA., H2 2013 36
Promedior, Inc., H2 2013 37
Inotek Pharmaceuticals Corporation, H2 2013 38
Angstrom Pharmaceuticals, Inc., H2 2013 39
FirstString Research, Inc., H2 2013 40
Sirnaomics, Inc., H2 2013 41
Resolvyx Pharmaceuticals, Inc, H2 2013 42
Stelic Institute & Co., H2 2013 43
Centocor Ortho Biotech, Inc., H2 2013 44
EyeCyte, Inc., H2 2013 45
Vascular Pharmaceuticals, Inc., H2 2013 46
PanOptica, Inc., H2 2013 47
Targa Therapeutics Corp., H2 2013 48
EyeGene, Inc., H2 2013 49
America Stem Cell, Inc., H2 2013 50
Ampio Pharmaceuticals, Inc., H2 2013 51
Assessment by Monotherapy Products, H2 2013 52
Assessment by Stage and Route of Administration, H2 2013 54
Assessment by Stage and Molecule Type, H2 2013 56
Diabetic Retinopathy Therapeutics - Drug Profile Updates 115
Diabetic Retinopathy Therapeutics - Discontinued Products 137
Diabetic Retinopathy Therapeutics - Dormant Products 138

List of Chart


Number of Products under Development for Diabetic Retinopathy, H2 2013 12
Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 17
Late Stage Products, H2 2013 18
Mid Clinical Stage Products, H2 2013 19
Early Clinical Stage Products, H2 2013 20
Discovery and Pre-Clinical Stage Products, H2 2013 21
Assessment by Monotherapy Products, H2 2013 52
Assessment by Route of Administration, H2 2013 53
Assessment by Stage and Route of Administration, H2 2013 54
Assessment by Molecule Type, H2 2013 55
Assessment by Stage and Molecule Type, H2 2013 56

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *